Jazz Pharmaceuticals (JAZZ) has released an update to notify the public and investors about an entry into a material definitive agreement.
Jazz Financing Lux S.à r.l., a Luxembourg subsidiary of Jazz Pharmaceuticals Public Limited Company, entered into a Repricing Amendment on January 19, 2024, to adjust the terms of the outstanding U.S. dollar term loans from May 5, 2021. This agreement allowed certain lenders to convert their loans into a new tranche, while Jazz Lux additionally borrowed over $201 million in principal amount of new loans to repay the non-converted outstanding loans. The new Tranche B-1 Dollar Term Loans have the same material terms as the initial loans, including maturity and security provisions.
For further insights into JAZZ stock, check out TipRanks’ Stock Analysis page.